Wise Ally Introduces An Affordable Ventilator

October 9, 2020

Wise Ally (Hong Kong) notes the COVID-19 pandemic is posing an unprecedented challenge to the world. Medical professionals and hospital workers across the globe are still struggling night and day to care for coronavirus patients.

Wise Ally also states while some patients might develop mild symptoms, however, there are 30%¹ of more severely infected patients have to stay in intensive care units supported by mechanical ventilators.

With over 35 million confirmed cases and 1 million deaths so far caused², ventilators have been in critical shortage globally since the beginning of the pandemic in late January 2020. There is an unmet need for rapidly deployable emergency-use ventilators with sufficient functionality to save patients with severe acute respiratory distress syndrome (ARDS).

In view of such distressing times, Wise Ally International Holdings Limited (Wise Ally) had decided to help save lives by developing the truly affordable and yet safe and easy-to-use ventilator – SapiVents which is built around a resuscitator bag usually found in ambulances and hospitals. SapiVents follows the strict guidance of Emergency Use Authorization under the FDA.

Its overall design, sensing technology and component selection is a major breakthrough in terms of cost by relying on a robust supply chain that is unlikely affected by shortages. It can certainly provide a temporary but crucial solution for emergency use offering basic ventilator functions during a critical situation.

Breathe Freely Campaign is a charitable initiative spearheaded by Wise Ally. With the generous funding from private and corporate donors and from the philanthropic sector, SapiVents is expected to undergo production and delivery by the end of 2020 to fight against COVID-19. At the production cost of less than US$300 each, not only SapiVents is by far the truly affordable non-invasive ventilator solution in the world, it will certainly ease up the pressure of hospitals in the most affected countries. All donations received will be used mainly on producing and delivering SapiVents via international NGOs and charity organizations.


Reference

  1. Report 9: Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand
  2. WHO Coronavirus Disease (COVID-19) Dashboard
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version